Literature DB >> 18656492

Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation.

Michiyo Kobayashi-Sakamoto1, Emiko Isogai, Kimiharu Hirose, Itsuo Chiba.   

Abstract

Osteoprotegerin (OPG) is a decoy receptor for the receptor activator of nuclear factor kappaB ligand (RANKL). However, the role of OPG in the endothelium remains unknown. In this study, we demonstrate that OPG stimulates the proliferation and migration of human microvascular endothelial cells (HMVECs). In addition, we show that treatment with integrin alpha(v)beta(3) or integrin alpha(v)beta(5) blocking antibody inhibits endothelial cell migration. In contrast, treatment with anti-alpha(v)beta(3) antibody or anti-alpha(v)beta(5) antibody alone did not inhibit OPG-induced proliferation. However, OPG-induced proliferation was inhibited when these antibodies were applied simultaneously. Furthermore, OPG evoked activation of extracellular signal-regulated kinase (ERK) 1/2, which has been linked to integrin alpha(v) activity. Taken together, these results suggest that integrins alpha(v)beta(3) and/or alpha(v)beta(5) contribute to endothelial cell proliferation and migration induced by OPG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656492     DOI: 10.1016/j.mvr.2008.06.004

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  12 in total

1.  Evaluation of isolation methods and culture conditions for rat bone marrow mesenchymal stem cells.

Authors:  Xueyuan Li; Yang Zhang; Guoxian Qi
Journal:  Cytotechnology       Date:  2012-09-26       Impact factor: 2.058

2.  Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function.

Authors:  Hongyan Zhao; Jianhong Gu; Nannan Dai; Qian Gao; Dong Wang; Ruilong Song; Wei Liu; Yan Yuan; Jianchun Bian; Xuezhong Liu; Zongping Liu
Journal:  Cytotechnology       Date:  2015-06-05       Impact factor: 2.058

3.  Glucocorticoid action in human corneal epithelial cells establishes roles for corticosteroids in wound healing and barrier function of the eye.

Authors:  Mahita Kadmiel; Agnes Janoshazi; Xiaojiang Xu; John A Cidlowski
Journal:  Exp Eye Res       Date:  2016-09-04       Impact factor: 3.467

4.  Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Jing-Ping Lin; Gang Zheng; Joel Moss
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

5.  RGD-tagged helical rosette nanotubes aggravate acute lipopolysaccharide-induced lung inflammation.

Authors:  Sarabjeet Singh Suri; Steven Mills; Gurpreet Kaur Aulakh; Felaniaina Rakotondradany; Hicham Fenniri; Baljit Singh
Journal:  Int J Nanomedicine       Date:  2011-12-02

6.  Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.

Authors:  Penny E Reid; Nicola J Brown; Ingunn Holen
Journal:  Mol Cancer       Date:  2009-07-15       Impact factor: 27.401

7.  Endothelium-specific deletion of Nox4 delays retinal vascular development and mitigates pathological angiogenesis.

Authors:  Xixiang Tang; Joshua J Wang; Jinli Wang; Hanna E Abboud; Yanming Chen; Sarah X Zhang
Journal:  Angiogenesis       Date:  2020-11-17       Impact factor: 9.596

8.  Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  BMC Cancer       Date:  2015-11-25       Impact factor: 4.430

9.  Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.

Authors:  Denis Lane; Isabelle Matte; Claude Laplante; Perrine Garde-Granger; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2013-11-23       Impact factor: 4.234

Review 10.  From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease.

Authors:  Sarah Dawson; Allan Lawrie
Journal:  Pharmacol Ther       Date:  2016-07-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.